Clinical trial shows promise in Alzheimer’s disease

A monoclonal antibody could be effective in patients with early symptoms of Alzheimer’s disease.

In a phase III published in JAMA Neurology, researchers randomly assigned more than 1,500 patients aged 60 to 85 years with early symptomatic Alzheimer’s disease to receive either intravenous donanemab or placebo every four weeks for a period of 76 weeks. Donanemab was administered in 700-milligram doses through the first three treatments and increased to 1,400-milligram doses for the remainder of the study period.

The researchers discovered that the patients in the donanemab group experienced lower brain amyloid levels and slower cognitive decline compared with those in the placebo group. The findings demonstrated the potential use of posttreatment amyloid levels as a surrogate biomarker of treatment efficacy in this patient population.

Read more: JAMA Neurology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.